The role of nicotine content information in smokers' subjective responses to nicotine and placebo inhalers.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

This study examined the role of information about nicotine content in smokers' subjective responses to nicotine and placebo inhalers, using the four conditions of the balanced-placebo design in a mixed within/between-subjects design.

Who Took Part

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

Twenty-four adult smokers (12 male) completed two laboratory sessions following overnight abstinence from smoking.

Participants were randomly assigned to receive either nicotine inhalers or placebo inhalers in both sessions but were told that they received a nicotine-containing inhaler in one session and a nicotine-free inhaler in the other.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

In each session participants completed subjective assessments before and after inhaler administration using visual analogue scales and the Brief Questionnaire of Smoking Urges.

What Was Measured

Topics PubMed links to this paper include Affect, Nebulizers and Vaporizers, Nicotine, Nicotinic Agonists, Psychometrics, Smoking and Nicotiana.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Human psychopharmacology), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.